In a short-term perspective, the company has interesting fundamentals.
Merck & Co., Inc. accounts for 4.58 % of our USA Portfolio. A trade is currently open since 10/23/2019 with a purchase price of $ 81.01. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
The group's activity appears highly profitable thanks to its outperforming net margins.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
With an enterprise value anticipated at 4.36 times the sales for the current fiscal year, the company turns out to be overvalued.